Open access
Open access
Powered by Google Translator Translator

Chest Medicine

[Preprint] Risk of severe COVID-19 is rare among fully vaccinated individuals in England.

14 Nov, 2021 | 20:10h | UTC

Commentary: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Original Study: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

 

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

Large populational study finds prior SARS-CoV-2 infection reduces the risk of breakthrough infection following mRNA vaccination.

14 Nov, 2021 | 20:12h | UTC

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Commentaries:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Commentary on Twitter

 

Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.

14 Nov, 2021 | 20:11h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Commentary on Twitter

 

RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

12 Nov, 2021 | 10:43h | UTC

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

 

Commentary on Twitter

 

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.

12 Nov, 2021 | 10:41h | UTC

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method – The Lancet Infectious Diseases

 

Commentary from the author on Twitter (thread – click for more)

 

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

12 Nov, 2021 | 10:32h | UTC

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID – The Lancet

Related:

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Boosting immunity to COVID-19 vaccines – “New studies highlight the immunological benefits of COVID-19 vaccine boosters, but questions remain over how to best make use of a limited global supply”.

12 Nov, 2021 | 10:37h | UTC

Boosting immunity to COVID-19 vaccines – Nature Medicine

 

ERS Guidelines: High-flow nasal cannula in acute respiratory failure.

12 Nov, 2021 | 10:29h | UTC

ERS Clinical Practice Guidelines: High-flow nasal cannula in acute respiratory failure – European Respiratory Journal

 

2022 ASA Guidelines for Management of the Difficult Airway.

12 Nov, 2021 | 10:31h | UTC

2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway – Anesthesiology

Related:

Consensus-based recommendations for management of the difficult airway: part 1. Difficult airway management encountered in an unconscious patient.

Difficult airway management in neonates and infants: knowledge of devices and a device-oriented strategy.

Consensus Guideline: Pediatric Airway Management in COVID-19 Patients

Guidelines for Awake Tracheal Intubation in Adults

Position Paper: Management of Unanticipated Difficult Airways in Children in Anesthetic Practice

Review: Difficult Airway Management Algorithms (several resources on the subject)

The Difficult Airway Trolley: A Narrative Review and Practical Guide

 

IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.

11 Nov, 2021 | 09:01h | UTC

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

 

Commentary on Twitter

 

Podcast | COVID Updates: The Outpatient Edition.

11 Nov, 2021 | 08:57h | UTC

COVID Updates: The Outpatient Edition – The Curbsiders

 

Commentary on Twitter

 

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

Related:

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.

11 Nov, 2021 | 08:53h | UTC

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

 

Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.

11 Nov, 2021 | 08:55h | UTC

COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR

 

[Preprint] RCT: In hypoxic but not critically ill patients with COVID-19, an intervention to increase prone positioning did not improve outcomes.

10 Nov, 2021 | 07:20h | UTC

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Related:

RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

 

Commentary from the author on Twitter (thread – click for more)

 

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

10 Nov, 2021 | 07:13h | UTC

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm – Science

Original viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes

Related:

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Opinion | Protective immunity after recovery from SARS-CoV-2 infection.

10 Nov, 2021 | 07:15h | UTC

Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases

 

Commentary on Twitter

 

Practice Review: COVID-19 rapid diagnostics.

9 Nov, 2021 | 01:52h | UTC

COVID-19 rapid diagnostics: practice review – Emergency Medicine Journal

 

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

9 Nov, 2021 | 01:46h | UTC

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic – JAMA Internal Medicine

Author Interview: Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Results With Persistent Physical Symptoms – JAMA Internal Medicine

Commentaries: Expert reaction to study looking at the association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms – Science Media Centre

Related:

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Commentary on Twitter

 

Review: Antineutrophil cytoplasmic antibody-associated interstitial lung disease.

10 Nov, 2021 | 06:46h | UTC

Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review – European Respiratory Review

 

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

 

Commentary on Twitter (thread – click for more)

 

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

 

Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

5 Nov, 2021 | 09:59h | UTC

Original study: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

News release: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

 

Commentary on Twitter

 

Review: SARS-CoV-2 indoor air transmission is a threat that can be addressed with science.

5 Nov, 2021 | 09:55h | UTC

SARS-CoV-2 indoor air transmission is a threat that can be addressed with science – Proceedings of the National Academies of Sciences

Related:

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

Editorial: Covid-19 has redefined airborne transmission

Covid-19: What do we know about airborne transmission of SARS-CoV-2?

Real-world data show that filters clean COVID-causing virus from air.

Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?”

Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission.

We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt.

Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers.

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

It’s not just SARS-CoV-2: Most respiratory viruses spread by aerosols.

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.